



Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030. India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

Date: August 31, 2020.

To
BSE Limited,
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Reg: Security Code No. 530233:

Sub: Outcome of Board Meeting dated August 31, 2020.

Dear Sir / Ma'am,

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors at their Meeting held today (i.e. **Monday, August 31, 2020**), inter-alia, considered and approved the following matters:

1. Un-audited Financial Results:

The Un-audited Financial Results for the quarter ended June 30, 2020 as recommended by the Audit Committee.

In this regard, we are enclosing herewith:

- Un-audited Financial Results for the quarter ended June 30, 2020.
- Limited Review Report received from the Statutory Auditor of the Company.

2. 31st Annual General Meeting:

The 31st Annual General Meeting of the Company will be held on Monday, September 28, 2020 at 11.00 a.m. The Annual General Meeting shall be held by means of Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") on account of outbreak of CoVID-19 (Coronavirus) Pandemic and in accordance with the relevant



Circulars issued by The Ministry of Corporate Affairs to transact the business as contained in the Notice convening the AGM.

The meeting of the Board of Directors commenced at 2.45 P.M. and concluded at 3.30 PM. The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in due course.

Kindly take the above on your record.

Thanking You.

Yours faithfully,

For AURO LABORATORIES LIMITED

Siddhartha Deorah



SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
[DIN: 00230796]

ANNEXURE - I

PART - I		(Rs. In Lakhs except EPS)			
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2020					
Sr. No.	Particulars	3 Months ended	Preceding 3 Months ended	Corresponding 3 Months ended in the Previous Year	For the Year Ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
1	Income from Operations				
	(a) Net Sales/Income from Operations (Net of GST)	1,222.46	942.83	1,371.56	4,379.06
2	Other Income	5.69	38.19	25.90	97.26
3	Total Revenue (1 + 2)	1,228.15	981.02	1,397.46	4,476.32
4	Expenses				
	a. Consumption of raw material	737.19	367.69	1,029.59	2,342.21
	b. Purchase of Stock-in-trade	1.23	30.86	24.10	56.61
	c. (Increase) / decrease in Finished Goods stock in trade and work in progress	0.90	119.97	(127.81)	49.18
	d. Employee benefits expense	126.20	184.91	102.65	527.54
	e. Finance Cost	7.97	9.84	15.52	46.63
	f. Depreciation and amortisation expenses	25.00	23.33	25.00	102.33
	g. Other Expenses	138.46	167.68	176.09	787.64
	Total Expenses (4)	1,036.95	904.29	1,245.14	3,912.14
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)	191.20	76.73	152.32	564.18
6	Exceptional items	-	-	-	-
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)	191.20	76.73	152.32	564.18
8	Extraordinary items	-	-	-	-
9	Profit / (Loss) before tax (7 ± 8)	191.20	76.73	152.32	564.18
10	Tax expense	-	-	-	-
	(a) Current tax expenses for current year	52.58	24.12	41.89	152.48
	(b) MAT credit (where applicable)	-	-	-	-
	(c) Deffered tax	-	6.25	-	6.25
11	Profit / (Loss) for the period from continuing operation (9± 10)	138.62	46.36	110.43	405.45
12	Profit / (Loss) for discontinuing operations	-	-	-	-
13	Tax expense of discontinuing operations	-	-	-	-
14	Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)	138.62	46.36	110.43	405.45
15	Other Comprehensive Income	7.69	11.22	10.68	11.22
16	Total Comprehensive Income for the period (14 ± 15)	146.31	57.58	121.11	416.67
17	Paid-up equity share capital	623.25	623.25	623.25	623.25
	(Face value of Rs. 10 each)				
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year)	-	-	-	1,526.51
19	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):				
	(a) Basic	2.22	0.74	1.77	6.51
	(b) Diluted	2.22	0.74	1.77	6.51

Notes:

- 1) The above unaudited financial results for the quarter ended 30th June, 2020 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 31st August 2020.
- 2) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) Figures for the quarter ended March 31, 2020 are the balanceing figures between the audited figures in respect of the full financial year and the published year to date figures of nine months ended December 31, 2019.
- 5) Limited review has been carried out by the Statutory Auditors of the Company.
- 6) Figures of previous period have regrouped / reclassified wherever necessary to facilitate comparison.

FOR & BEHALF OF THE BOARD OF DIRECTORS
 AURO LABORATORIES LIMITED

SIDDHARTHA DEORAH
 WHOLE TIME DIRECTOR
 DIN NO. 00230796



Place : Mumbai
 Date : 31.08.2020



KHURDIA JAIN & CO.
CHARTERED ACCOUNTANTS

To,
The Board of Directors,
Auro Laboratories Limited.

We have reviewed the standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the Quarter ended June 30, 2020, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.

This Statement is the responsibility of the Company's Management and had been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in accordance with generally accepted accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khurdia Jain & Co.
Chartered Accountants

Abhinav Sampat Khurdia
Partner

Membership No. 126358

Firm Reg. No. 120263W

Place: Mumbai

Date: 31st August 2020

UDIN : 20126358AAAABA8228

